Healthcare Biz Review: Salix Pharmaceuticals Plunges, Amyris Sees Negative Cash Flow

NeurogesX’s (NASDAQ:NGSX) Qutenza patch was not recommended by the Food and Drug Administration for the treatment for nerve pain related to HIV-associated peripheral neuropathy.

Investing Insights: Traders Analyze Earnings of These 2 Healthcare Stocks.

Salix Pharmaceuticals (NASDAQ:SLXP) shares plunged. The Food and Drug Administration provides relatively lenient clinical study guidelines for would-be makers of a generic version of Salix’s Xifaxan drug. Salix closed yesterday near its 52-week high.

Amyris (NASDAQ:AMRS) shares tanked after the renewable products company says it is no longer forecasting positive cash flow for 2012. It will instead seek as much as $60 million in additional financing. AMRS is running into execution risk as it scales up its production of next-generation biofuels, Raymond James says: “It will clearly take time for the growth curve to materialize.”

Earnings Report: Athenahealth Inc. Fourth Quarter Earnings Sneak Peek.

To contact the reporter on this story: Tanya Harding at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com